

# Medicine: autologous anti-CD19-transduced CD3+ cells (KTE-X19) (brand name: Tecartus®)

Kite, a Gilead Company

The Scottish Medicines Consortium (SMC) has assessed Tecartus® for the treatment of adults with mantle cell lymphoma that has relapsed (come back after treatment) or is refractory (has stopped responding to treatment). It is given after two or more treatments, including a Bruton's tyrosine kinase (BTK) inhibitor (a type of medicine used to treat lymphoma) have stopped working. This document summarises the SMC decision and what it means for patients.

## What has SMC said?

After careful consideration, SMC has accepted Tecartus® on an interim basis (interim acceptance) for the treatment of mantle cell lymphoma as described above. Interim acceptance is an option available to SMC for medicines which have received a conditional marketing authorisation or licence. This means that Tecartus® is accepted for use subject to ongoing evaluation and reassessment once further evidence is available.

This advice takes into account a confidential discount offered by the pharmaceutical company that improves the cost-effectiveness of Tecartus®. In addition, SMC was able to apply a more [flexible approach\\*](#) in the assessment, as it is for a rare condition where patients are likely to have a life expectancy of less than three years with currently available treatments.

## What does SMC's decision mean for patients?

The decision to accept Tecartus® on an interim basis means that if your healthcare professional thinks that it is the right medicine for you, you should be able to have the treatment on the NHS in Scotland. Once further evidence is available, SMC will reassess the medicine and provide an updated decision on its routine availability in NHSScotland.



## What is Tecartus® used for?

Tecartus® is used for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive cancer of a type of white blood cells called T lymphocytes. The main symptom of MCL is a lump or lumps in the neck, armpit or groin. These lumps are caused by a build-up of lymphoma (cancer) cells in the lymph nodes. Symptoms can also include high temperatures (fever), night sweats and weight

\*<https://www.scottishmedicines.org.uk/how-we-decide/pace/>

loss. Tecartus® is used when two or more treatments have failed and there are limited treatment options available to patients.

## How does Tecartus® work?

Tecartus® is a new innovative type of medicine called CAR-T cell therapy. It uses the patient's own immune cells (T-cells) to destroy the cancer cells. The patient's T-cells are collected and modified in the laboratory to create CAR-T cells. These cells are then given back to the patient through a drip into the vein. The CAR-T cells bind to and kill the cancer cells.

## How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC consider the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of Tecartus® by looking at the SMC Detailed Advice Document (SMC2351).

## More information

The organisation below can provide more information and support for people with mantle cell lymphoma and their families. SMC is not responsible for the content of any information provided by external organisations.

### Lymphoma Action



<https://lymphoma-action.org.uk>



0808 808 5555

You can find out more about Tecartus® in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<https://www.ema.europa.eu/en>